TEVA Teva Pharmaceutical Industries
- 16.880
- +0.630+3.88%
- 16.870
- -0.010-0.06%
Teva Pharmaceutical Industries News
Unusual Options Activity: SNOW, TEVA and Others Attract Market Bets, SNOW V/OI Ratio Reaches 105.9
EST May 13th Closing Delivery - In the last three hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Teva Pharmaceutical Industries Options Spot-On: On May 13th, 136.54K Contracts Were Traded, With 875.24K Open Interest
On May 13th ET, $Teva Pharmaceutical Industries(TEVA.US)$ had active options trading, with a total trading volume of 136.54K options for the day, of which put options accounted for 5.11% of the total
Unusual Options Activity: WBD, TEVA and Others Attract Market Bets, WBD V/OI Ratio Reaches 1308.7
EST May 13th Afternoon Delivery - In the last two hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Teva Pharmaceuticals Price Target Raised to $20.00/Share From $19.00 by Piper Sandler
Teva Pharmaceuticals Price Target Raised to $20.00/Share From $19.00 by Piper Sandler
Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
Piper Sandler: Teva Pharmaceutical Indus (TEVA.US) rating was confirmed, adjusted from an increase to an increase rating, and the target price was adjusted from $19.00 to $20.00.
Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus with a Overweight and raises the price target from $19 to $20.
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?
These large-cap stocks were the best performers in the last week. Are they in your portfolio?Teva Pharmaceutical Industries (NYSE:TEVA) shares surged 16.24% after the company reported mixed Q1 financi
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Teva Pharmaceuticals Is Maintained at Overweight by Barclays
Teva Pharmaceuticals Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus with a Overweight and raises the price target from $17 to $20.
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 25.47% Barclays $17 → $20 Maintains Overweight 03/08/2024 -12.17% JP Morgan → $14 Upgrades Unde
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript
Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
US Stock Nuggets | Power stocks are once again the focus of AI investment! Vistra and Constellation hit new highs
Nvidia's exclusive liquid cooling supplier Vertiv continued to strengthen, and the increase has doubled during the year; high-performing stocks have risen significantly! Toast and Teva Pharmaceuticals surged about 13% after the earnings report.
10-Q: Quarterly report
Teva Pharmaceutical Industries Options Spot-On: On May 8th, 130.42K Contracts Were Traded, With 838.87K Open Interest
On May 8th ET, $Teva Pharmaceutical Industries(TEVA.US)$ had active options trading, with a total trading volume of 130.42K options for the day, of which put options accounted for 17.32% of the total
Teva Stock Jumps on Q1 Earnings, Successful Trial Results
Research Alert: CFRA Keeps Hold Opinion On Shares Of Teva Pharmaceutical Industries Limited
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our 12-month target by $4 to $18
Analysis
Price Target
No Data
